Promising Pipeline | Explore C4 Therapeutics' lead candidate CFT1946, a BRAF V600X degrader showing superior efficacy in preclinical studies and early clinical trials |
Clinical Progress | Delve into early clinical data revealing encouraging anti-tumor activity and favorable safety profile of CFT1946 compared to historical benchmarks |
Market Potential | Learn how CFT1946's unique mechanism and safety profile could position it as a preferred treatment across various BRAF V600 mutant-driven cancers |
Analyst Outlook | BMO Capital Markets rates C4 Therapeutics as Outperform with a $20 price target, suggesting significant upside potential from current levels |
Metrics to compare | CCCC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCCCCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.6x | −7.0x | −0.2x | |
PEG Ratio | −0.06 | 0.01 | 0.00 | |
Price/Book | 1.4x | 1.8x | 2.6x | |
Price / LTM Sales | 10.1x | 15.3x | 2.6x | |
Upside (Analyst Target) | - | 124.6% | 76.9% | |
Fair Value Upside | Unlock | −9.3% | 14.9% | Unlock |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.